ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 腎細胞癌診療の新しい展開
文献概要
要旨 腎細胞癌は，転移の有無にかかわらず根治的腎摘除術を行い，術後アジュバント（ネオアジュバント）療法を行うのが一般的な治療法である。しかし，診断時にすでに進行癌で前述の治療法を行えないか，行うと反対に短命となる症例が存在するのも事実である。最近では，治療前に予後予測因子により手術の適応の有無を判定し，患者の状態に応じた適切な治療法を選択するようになってきている。抗腫瘍効果が確認された免疫療法，分子標的治療も単独では根治療法となり得ない現状では，手術療法をベースとした集学的治療を今後も行っていくことになる。
参考文献
1）Konnak JW and Grossman HB：Renal cell carcinoma as an incidental finding. J Urol 134：1094-1096, 1985
2）北原聡史，岡 薫，山田清勝，他：超音波による腎のスクリーニング―腎癌の早期発見．臨泌 37：1079-1084，1983
3）小林幹男，松尾康滋，戸塚芳宏，他：腎細胞癌；診断の契機に関する臨床的検討．日泌尿会誌 81：686-693，1990
4）Motzer RJ, Bander NH and Nanus DM：Renal cell carcinoma. N Engl J Med 335：865-869, 1996
5）古賀成彦，錦戸雅春，草場泰之，他：長崎県において2001，2002年に発生した腎細胞癌の実態調査．西日泌 65（増刊号）：106，2003
6）Robson JC, Bernard MC and Anderson W：The resalt of radical nephrectomy for renal cell carcinoma. J Urol 101：297-301, 1969
7）Ralfa S：Renal cell carcinoma；natural history and results of treatment. Cancer 25：26, 1970
8）Holland JM：Cancer of the kidney：Natural history and staging. Cancer 32：1030-1034, 1973
9）Neves RJ, Zinke H and Taylor WF：Metastatic renal cell cancer and radical nephrectomy：identification of prognostic factors and patient survival. J Urol 139：1173-1176, 1988
10）Sene AP, Hunt L, McMahon RF, et al：Renal carcinoma in patients undergoing nephrectomy：Analysis of survival and prognostic factors. Br J Urol 70：125-134, 1992
11）Lam JS, Goel RH, Pantuck RA, et al：Long term survival following nephrectomy for renal cell carcinoma：The 15 year university of Carifornia-Los Anzels experience. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol, 2006
12）Leibovich RC, Cheville JC, Lohse CM, et al：A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma：a stratification tool for prospective clinical trials. J Urol 174：1759-1763, 2005
13）Bumpus HC Jr：The apparent disappearance of pulmonary metastasis in a case of hyper nephroma folling nephrectomy. J Urol 20：185, 1928
14）Selwyn FJ, Halperin JP and Gordon M：Idiopathic regression of metastases from renal cell carcinoma. J Urol 118：538-542, 1977
15）Snow RM, Schellhammer PF：Spontaneous regression of metastatic renal cell carcinoma. Urology 20：177-181, 1982
16）小林幹男，田村芳美，岡村桂吾，他：腎細胞癌における手術療法の検討．第1報：腎摘除術について．日泌尿会誌 82：122-129，1991
17）小林幹男，黒川公平，戸塚芳宏，他：腎細胞癌における手術療法の検討．第2報：腫瘍血栓除去術について．日泌尿会誌 82：130-138，1991
18）Mickisch GH, Garin A, van Poppel H, et al：Radical nephrectomy plus interferon-alfa-basaed immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma：a randomised trial. Lancet 358：966-970, 2001
19）Flanigan, RC, Salmon SE, Blumenstein BA, et al：Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345：1655-1659, 2001
20）Flanigan RC, Mickisch G, Sylvester R, et al：Cytoreductive nephrectomy in patients with metastatic renal cancer：a combined analysis. J Urol 171：1071-1076, 2004
21）Fossa SD, Kramar A and Droz JP：Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A：1310-1314, 1994
22）Patard JJ, Leray E, Cindolo L, et al：Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 172：858-862, 2004
23）Motzer RJ, Mazumdar M, Bacik J, et al：Survival and prognostic stratification of 670 patients with advansed renal cell carcinoma. J Clin Oncol 17：2530-2540, 1999
24）Motzer RJ, Bacik J, Schwartz LH, et al：Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22：454-463, 2004
25）Mekhail TM, Abou-Jawde RM, Boumerhi G, et al：Validation and extention of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23：822-841, 2005
26）Sorbellini M, Kattan MW, Synder ME, et al：A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell carcinoma. J Urol 173：48-51, 2005
27）Lam JS, Shvarts O, Leppert JT, et al：Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on validated prognostic nomogram and risk group stratification system. J Urol 174：466-472, 2005
28）野口純男，執印太郎，窪田吉信，他：転移性腎癌の予後因子の検討．日泌尿会誌 86：1279-1286，1995
29）O'Dea MJ, Zincke H, Utz DC, et al：The treatment of renal cell carcinoma with solitary metastasis. J Urol 120：540-544, 1978
30）Han KR, Pantack AJ, Bui MH, et al：Number of metastatic sites rather than location dicates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61：314-319, 2003
31）Herrlinger A, Schrott KM, Schott G, et al：What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma? J Urol 146：1224-1227, 1991
32）Canfield SE, Kamat AM, Sanchez-Ortiz RF, et al：Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease（clinical stage TxN1-2M0）：The impact of aggressive surgical resection on patient outcome. J Urol 175：864-869, 2006
33）中沢速和：腎癌におけるリンパ節郭清術の適応と範囲．泌尿器外科 18：573-577，2005
34）Middleton RG：Surgery for metastatic renal cell carcinoma. J Urol 97：973-977, 1967
35）Skinner DG, Colvin RB, Vermillion CD, et al：Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28：1165-1177, 1971
36）Barney JD, Churchill EJ：Adenocarcinoma of the kidney with metastasis to the lung cured by nephrectomy and lobectomy. J Urol 42：298-300, 1961
37）Dineen MK, Pastore RD, Emrich LJ, et al：Result of surgical treatment of renal cell carcinoma with solitary metastasis. J Urol 140：277-279, 1988
38）Thomford NR, Woolner NB and Clagett OT：The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg 49：357-363, 1965
39）Dekernion JB, Ramming KP and Smith RB：The natural history of metastatic renal cell caecinoma：a computer analysis. J Urol 120：148-152, 1978
40）岡田信一郎，小林俊介，藤村重文：転移性肺腫瘍に対する外科治療．泌尿器外科 4：1255-1259，1991
41）野並芳樹，久米基彦，笹栗志朗，他：腎癌転移例に対する手術と予後影響因子の検討．胸部外科 56：41-45，2003
42）Kollender Y, Bickels J, Price WM, et al：Metastatic renal cell carcinoma of bone：Indication and technique of surgical intervention. J Urol 164：1505-1508, 2000
43）Mori Y, Kondziolka D, Flickinger JC, et al：Stereotactic radiotherapy for brain metastases from renal cell carcinoma. Cancer 83：344-353, 1998
44）Bloom HJG：Hormon-induced and spontaneous regression of metastatic renal cancer. Cancer 32：1066-1070, 1973
45）Hrushesky W and Murphy GP：Current therapy of the therapy of advanced renal cell carcinoma. J Surg Oncol 9：277-288, 1977
46）Medical Research Council Renal Cancer Collaborators：Interferon-α and survival in metastatic renal cell carcinoma：early results of randomized controlled trial. Lancet 353：14-17, 1999
47）Mittelman A, Alert DJ and Murphy GP：Lomustin treatment of metastatic renal cell carcinoma. JAMA 225：32-35, 1973
48）Hann DM：Single agent therapy for renal cell carcinoma：CCNU, vinblastin, Thio-TEPA or bleomycin. Cancer Treat Rep 61：1585-1587, 1977
49）小林幹男，今井強一，中井克幸，他：腎細胞癌の治療．第2報：ACNU & VBL併用療法．泌尿紀要 3：373-383，1986
50）von Roemeling R, Rabatin JT, Fraley EE, et al：Progressive metastatic renal cell carcinoma controllesd by continuous 5-Fluoro-2-deoxyuridine infusion. J Urol 139：252-262, 1988
51）Nanus DM, Gardio A, Milovsky MI, et al：Active chemotherapy for sarcomatoid and rapidly progressive renal cell carcinoma. Cancer 101：1345-1551, 2004
52）Fossa SD, Martinelli G, Otto U, et al：Recombinantinterferon alfa-2a with or without vinblastin in metastatic renal cell carcinoma. Result of a European multicenter phase Ⅲ study. Ann Oncol 3：301-305, 1992
53）Igarashi T, Marumo K, Onishi T, et al：Interferon alfa and 5-furuorouracil therapy in patients with metastatic renal cell cancer：an open multicenter trial. Urology 53：53-59, 1999
54）Atzpodien J, Kirschner H, Haqnninen EI, et al：Interleukin-2 in combination with interferon alfa and 5-Furuorouracil for metastatic renal cell cancer. Eup J Cancer 29A（Suppl 5）：s6-s8, 1993
55）古賀成彦，金武 洋：腎細胞癌の免疫療法．臨泌 54：993-999，2000
56）志田圭三，山中英寿，伊藤善一，他：泌尿器悪性腫瘍に対するUFTのPhaseⅡ Study．癌と化学療法 11：1307-1314，1984
57）Kobayashi M, Imai K, Hidetoshi Y, et al：Combination therapy of renal cell carcinoma with Interferon-α and UFT（or FT-207）. J Jpn Soc Cancer 24：1437-1446, 1989
58）Dekernion JB, Sarna G, Figlin R, et al：The treatment of renal cell carcinoma with human leukocyte alfa interferon. J Urol 130：1063-1066, 1983
59）Quesada JR, Swanson DA, Trindade A, et al：Renal cell carcinoma：Antitumor effects of leukocyte interferon. Cancer Res 43：940-947, 1983
60）Neidhart JA, Gagen MM, Young D, et al：Interferon-α therapy of renal cancer. Cancer Res 44：4140-4143, 1984
61）Recombinant Interferon Gamma（S-6810）Research Group on renal cell carcinoma：PhaseⅡ study of recombinant interferon gamma（S-6810）on renal cell carcinoma. Cancer 60：929-933, 1987
62）Aultizky W, Gastl G, Aultizky WE, et al：Successful treatment of metastat renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 7：1875-1884, 1989
63）Muke JJ, Shu S, Schwarz SL, et al：Adoptive immunotheraoy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225：1487-1489, 1984
64）Rosenberg SA, Spiess P, Lafreniere R, et al：A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233：1318-1321, 1986
65）Rosenberg SA, Yang JC, White DE, et al：Durability of complete responses in patients with metastatic cancer treated with high dose interleukin-2：identification of bthe antigens medicating response. Annu Surg 228：307-319, 1988
66）Yang JC, Topalian SL, Parkinson D, et al：Randomized comparison of high-dose and low-dose intra venous interleukin-2 for the therapy of metastatic renal cell carcinoma：an interim report. J Clin Oncol 12：1572-1576, 1994
67）Fyfe G, Fisher RJ, Rosenberg SA, et al：Results of treatment of 255 patients with metastatic RCC who received high-dose interleukin-2 therapy. J Clin Oncol 13：688-696, 1995
68）阿曽佳郎，本間之夫，田崎 寛，他：S-6820（遺伝子組み換え型ヒトインターロイキンー2）のインターフェロン無効腎細胞癌に対する第Ⅱ相試験．泌尿器外科 8：75-86，1995
69）McDermott DF, Regan MM, Clark JI, et al：Randomized phase Ⅲ trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23：133-141, 2005
70）冨田善彦：腎細胞癌有転移症例の検討．臨泌 54：829-839，2000
71）Stebbing J and Gore M：The current status of interferon-alpha treatment in advanced renal cancer. BJU Int 87：599-601, 2001
72）Holtel L, Zelle-Reiser C, Gander H, et al：Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendric cells. Clin Cancer Res 8：3368-3376, 2002
73）Jocham D, Richter A, Hoffmann L, et al：Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy：phase Ⅲ, randomized controlled trial. Lancet 363：594-599, 2004
74）冨田善彦：進行性腎細胞癌に対する骨髄非破壊的前処置を用いた同種造血幹細胞移植療法（ミニ移植）．Reduced intensity stem cell transplantation（RIST）の現状．泌尿器外科 17：675-679，2004
75）Latif F, Tory K, Gnarra J, et al：Identification of the von Hippel-Lindeau disease tumor suppressor gene. Science 260：1317-1320, 1993
76）Gnarra JR, Zhou S, Merrill MJ, et al：Post-transcriptional reguration of vascular endotherial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Nat Acad Sci USA 93：10589-10594, 1996
77）Turner KJ, Moor JW, Jones A, et al：Expression of hypoxia-inducible factors in human renal cancer：relationship to angiogenesis and to the von Hippel-Lindeau gene mutation. Cancer Res 62：2957-2961, 2002
78）Wilhelm ST, Carter C, Tang LY, et al：BAY 43-9006 exhibits broad spectorum oral antitumor activity and targets the RAF/MEK/FRK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis angiogenesis. Cancer Res 63：7099-7109, 2004
79）Escudier B, Szczlik C, Tang LY, et al：Randomized phase Ⅲ trial of the RAF kinase and VEGF inhibitor sorafenib（BAY-43-9006）in patients with advanced metastatic renal cell carcinoma. J Clin Oncol（ASCO Annual Meeting Proceedings） 23：Abstr. No. 4510, 2005
80）Motzer RJ, Rini BI, Michaelson MD, et al：phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma（RCC）. J Clin Oncol（ASCO Annual Meetings Proceedings） 23：Abstr. No. 16s, 2005
81）Motzer RJ, Huston TE, Tomczak P, et al：Phase Ⅲ randomized trial of sunitinib malate（SU 11248）versus interferon-alfa（IFN-a）as first-line systemic therapy for patients with metastatic renal cell carcinoma（mRCC）. J Clin Oncol（ASCO Annual Meeting Proseedings） 24：Abstr. No. LBA3, 2006
掲載誌情報
